The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.
Structure−Activity Relationship Studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a Potent Inhibitor of Leukotriene A<sub>4</sub> (LTA<sub>4</sub>) Hydrolase
作者:Thomas D. Penning、Nizal S. Chandrakumar、Barbara B. Chen、Helen Y. Chen、Bipin N. Desai、Stevan W. Djuric、Stephen H. Docter、Alan F. Gasiecki、Richard A. Haack、Julie M. Miyashiro、Mark A. Russell、Stella S. Yu、David G. Corley、Richard C. Durley、Brian F. Kilpatrick、Barry L. Parnas、Leslie J. Askonas、James K. Gierse、Elizabeth I. Harding、Maureen K. Highkin、James F. Kachur、Suzanne H. Kim、Gwen G. Krivi、Doreen Villani-Price、E. Yvonne Pyla、Walter G. Smith、Nayereh S. Ghoreishi-Haack
DOI:10.1021/jm990496z
日期:2000.2.1
program, SC-22716 (1, 1-[2-(4-phenylphenoxy)ethyl]pyrrolidine) was identified as a potent inhibitor of LTA(4) hydrolase. Structure-activity relationship (SAR) studies around this structural class resulted in the identification of a number of novel, potent inhibitors of LTA(4) hydrolase, several of which demonstrated good oral activity in a mouse ex vivo whole blood assay.
[EN] LTA4 HYDROLASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HYDROLASE LTA4
申请人:G.D. SEARLE & CO.
公开号:WO1996011192A1
公开(公告)日:1996-04-18
(EN) The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as psoriasis, ulcerative colitis, IBD and asthma.(FR) L'invention concerne des composés de la formule (Ar1-Q-Ar2-Y-R-Z et leurs sels pharmaceutiquement acceptables, dans laquelle Ar1 et Ar2 sont éventuellement des fractions aryles substituées, Z est éventuellement une fraction substituée contenant un azote, cette fraction pouvant être une amine acyclique, cyclique ou bicyclique, ou éventuellement une fraction hétéroaromatique substituée monocyclique ou bicyclique contenant un azote; Q est un groupe de liaison pouvant lier deux groupes aryles; R est une fraction alkylène; Y est une fraction de liaison pouvant lier un groupe aryle à une fraction alkylène, et Z est lié à R par l'intermédiaire d'un atome d'azote. Les composés et les compositions pharmaceutiques de l'invention sont utiles pour traiter des maladies inflammatoires induites par la production de LTB4, telles que le psoriasis, la colite ulcérative, IBD et l'asthme.
[EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
申请人:UNIV MICHIGAN STATE
公开号:WO2022165198A1
公开(公告)日:2022-08-04
A liner in a label-liner combination is provided with a die cut portion made in the liner. The die cut portion is aligned with at least one edge in a label and a front side of the liner is attached to a backside of the label. The die cut portion of the liner is adapted to be removed from the liner when the label is removed from the label-liner combination. Dimensions, and orientation, and a location of the die cut portion in the liner are adapted to allow the label to be removed from the label-liner combination and applied to a surface by digits of a hand without touching an adhesive coating on the backside of the label and adapted to maintain proper printer waste liner spool operations when the liner is wound after application of the label.
(2-Cyan-2-oximinoacetyl)-aminosäure-Derivate der allgemeinen Formel (I)
in welcher
R und R¹ die in der Beschreibung gegebenen Bedeutungen haben und ihre Verwendung zur Bekämpfung von Schädlingen.
Die neuen (2-Cyan-2-oximinoacetyl)-aminosäure-Derivate der allgemeinen Formel (I) können nach bekannten Verfahren hergestellt werden, so z.B. aus geeigneten 2-Cyan-2-oximinoessigsäureestern mit geeigneten Aminen oder aus geeigneten carboxyaktivierten Derivaten von Carbonsäuren mit Aminen u.a.